• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对于接受减瘤手术及腹腔热灌注化疗治疗腹膜癌病的患者,术后C反应蛋白动力学可预测术后并发症。

Postoperative C-reactive protein kinetics predict postoperative complications in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.

作者信息

Asmar Antoine El, Bendavides Melissa, Moreau Michel, Hendlisz Alain, Deleporte Amélie, Khalife Maher, Donckier Vincent, Liberale Gabriel

机构信息

Department of Surgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, 121, Blvd. de Waterloo, 1000, Brussels, Belgium.

Department of Statistics, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

出版信息

World J Surg Oncol. 2020 Nov 26;18(1):311. doi: 10.1186/s12957-020-02081-6.

DOI:10.1186/s12957-020-02081-6
PMID:33243287
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7694318/
Abstract

BACKGROUND

Relatively high morbidity rates are reported after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). However, early predictors of complications after CRS plus HIPEC have not been identified. The aim of this study was to evaluate the predictive role of early postoperative serum C-reactive protein (CRP) level (Day 2-4) for the detection of post-operative complications.

PATIENTS AND METHODS

We performed a retrospective study including 94 patients treated with complete CRS (R1) and HIPEC for PC from various primary origins (2011-2016). Post-operative complications were recorded. The values for postoperative inflammatory markers (white blood cells [WBC] and platelet counts, CRP) were compared between the different groups.

RESULTS

CRP on post-operative days 2-4 was significantly higher in patients with than without complications (124 mg/L vs 46 mg/L; p < 0.0001) and higher in those with more major complications (162 mg/L vs 80 mg/L; p < 0.0012). WBC and platelet counts showed no difference within 5 days postoperatively.

CONCLUSION

CRP levels, and kinetics mainly, between post-operative day 2 and 4, are decisive predictive markers of early and late post-operative complications after CRS plus HIPEC. The presence of post-operative complications should be suspected in patients with a high CRP mean, and a plateau level (days 2-4).

摘要

背景

细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)后报告的发病率相对较高。然而,CRS联合HIPEC术后并发症的早期预测指标尚未明确。本研究的目的是评估术后早期血清C反应蛋白(CRP)水平(第2 - 4天)对术后并发症检测的预测作用。

患者与方法

我们进行了一项回顾性研究,纳入了94例2011 - 2016年因各种原发灶接受根治性CRS(R1)和HIPEC治疗的PC患者。记录术后并发症情况。比较不同组之间术后炎症标志物(白细胞[WBC]、血小板计数、CRP)的值。

结果

有并发症的患者术后第2 - 4天的CRP显著高于无并发症的患者(124 mg/L对46 mg/L;p < 0.0001),且并发症更严重的患者CRP更高(162 mg/L对80 mg/L;p < 0.0012)。术后5天内WBC和血小板计数无差异。

结论

术后第2天至第4天的CRP水平及其动态变化主要是CRS联合HIPEC术后早期和晚期并发症的决定性预测标志物。CRP均值高且呈平台期水平(第2 - 4天)的患者应怀疑存在术后并发症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3866/7694318/f19fa90fb599/12957_2020_2081_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3866/7694318/f19fa90fb599/12957_2020_2081_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3866/7694318/f19fa90fb599/12957_2020_2081_Fig1_HTML.jpg

相似文献

1
Postoperative C-reactive protein kinetics predict postoperative complications in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.对于接受减瘤手术及腹腔热灌注化疗治疗腹膜癌病的患者,术后C反应蛋白动力学可预测术后并发症。
World J Surg Oncol. 2020 Nov 26;18(1):311. doi: 10.1186/s12957-020-02081-6.
2
Serum procalcitonin improves diagnosis of infectious complications after CRS/HIPEC.血清降钙素原有助于提高 CRS/HIPEC 术后感染性并发症的诊断。
World J Surg Oncol. 2023 Jan 12;21(1):5. doi: 10.1186/s12957-022-02884-9.
3
Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.细胞减灭术和腹腔内热化疗后腹膜恶性肿瘤患者的肠皮肤瘘:发病率、管理及结局
Surg Oncol. 2016 Sep;25(3):315-20. doi: 10.1016/j.suronc.2016.05.025. Epub 2016 May 24.
4
[Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].1384例腹膜癌病患者接受细胞减灭术加腹腔内热灌注化疗的疗效
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Mar 25;24(3):230-239. doi: 10.3760/cma.j.cn.441530-20201110-00603.
5
A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.一种用于预测减瘤手术联合热灌注腹腔化疗后主要并发症的新型工具。
Ann Surg Oncol. 2016 May;23(5):1609-17. doi: 10.1245/s10434-015-5012-3. Epub 2015 Dec 17.
6
Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.新辅助化疗联合腹腔热灌注化疗治疗结直肠腹膜转移患者的安全性和有效性:一项回顾性研究。
World J Surg Oncol. 2021 May 17;19(1):151. doi: 10.1186/s12957-021-02255-w.
7
Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.腹腔镜检查在腹膜转移癌患者中是安全的,不会延迟含热灌注化疗的细胞减灭术。
Am Surg. 2022 Apr;88(4):698-703. doi: 10.1177/00031348211048819. Epub 2021 Nov 3.
8
High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy.结直肠癌腹膜转移患者行细胞减灭术和腹腔热灌注化疗后,高等级术后并发症影响生存结局。
BMC Cancer. 2021 Jan 7;21(1):41. doi: 10.1186/s12885-020-07756-7.
9
Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?对于接受细胞减灭术和腹腔内热灌注化疗(HIPEC)治疗的患者,术后早期腹腔内化疗(EPIC)会产生不同效果吗?
Int J Hyperthermia. 2016 May;32(3):281-8. doi: 10.3109/02656736.2015.1135485. Epub 2016 Feb 10.
10
Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.出院后接受减瘤手术加腹腔热灌注化疗患者主要并发症的延迟出现
J Surg Oncol. 2015 Mar;111(3):324-7. doi: 10.1002/jso.23834. Epub 2014 Dec 31.

引用本文的文献

1
Early prediction of postoperative infection using inflammatory markers after cytoreductive surgery for peritoneal carcinomatosis.腹膜癌减瘤手术后使用炎症标志物对术后感染进行早期预测。
World J Gastrointest Surg. 2025 May 27;17(5):101323. doi: 10.4240/wjgs.v17.i5.101323.
2
Invited Editorial About the Clinical Significance of "Predictive Value of C-Reactive Protein for Infectious Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Single-Center Prospective Study" by Charbonneau et al. : Postoperative CRP to Predict Postoperative Complications: A Myth or Reality?特邀社论:关于沙博诺等人的《C反应蛋白对减瘤手术及热灌注化疗后感染性并发症的预测价值:一项单中心前瞻性研究》的临床意义:术后CRP预测术后并发症:是神话还是现实?
Ann Surg Oncol. 2024 Dec;31(13):8488-8490. doi: 10.1245/s10434-024-16339-w. Epub 2024 Oct 7.
3

本文引用的文献

1
Epithelial ovarian cancer.上皮性卵巢癌。
Lancet. 2019 Mar 23;393(10177):1240-1253. doi: 10.1016/S0140-6736(18)32552-2.
2
Sclerosing encapsulating peritonitis as a potential complication of cytoreductive surgery and HIPEC: Clinical features and results of treatment in 4 patients.硬化性包裹性腹膜炎作为细胞减灭术和腹腔热灌注化疗的潜在并发症:4例患者的临床特征及治疗结果
Surg Oncol. 2018 Dec;27(4):657-662. doi: 10.1016/j.suronc.2018.08.005. Epub 2018 Aug 28.
3
C-reactive protein as early predictor of complications after minimally invasive colorectal resection.
Predictive Value of C-Reactive Protein for Infectious Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Single-Center Prospective Study.C 反应蛋白对细胞减灭术和腹腔热灌注化疗后感染并发症的预测价值:一项单中心前瞻性研究。
Ann Surg Oncol. 2024 Dec;31(13):8538-8548. doi: 10.1245/s10434-024-15986-3. Epub 2024 Aug 12.
4
C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.C反应蛋白:病理生理学、诊断、检测结果假阳性及面向临床医生的新型诊断算法
Diseases. 2023 Sep 28;11(4):132. doi: 10.3390/diseases11040132.
5
Early postoperative CRP predicts major complications following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).术后早期C反应蛋白可预测减瘤手术(CRS)及热灌注化疗(HIPEC)后的主要并发症。
Pleura Peritoneum. 2023 Jun 2;8(3):113-121. doi: 10.1515/pp-2022-0203. eCollection 2023 Sep.
6
Risk factors of temperature increase after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy.减瘤手术联合腹腔热灌注化疗后体温升高的危险因素。
Front Oncol. 2023 Mar 22;13:1120499. doi: 10.3389/fonc.2023.1120499. eCollection 2023.
7
Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy.纳武利尤单抗联合紫杉醇治疗恶性胸腔积液的疗效及安全性
BMC Pharmacol Toxicol. 2023 Mar 1;24(1):13. doi: 10.1186/s40360-023-00653-2.
8
Implications of peritoneal cancer index distribution on patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.腹膜癌指数分布对接受细胞减灭术和腹腔内热灌注化疗患者的影响。
Pleura Peritoneum. 2022 Apr 26;7(2):95-102. doi: 10.1515/pp-2021-0150. eCollection 2022 Jun 1.
C反应蛋白作为微创结直肠切除术后并发症的早期预测指标
J Surg Res. 2017 Apr;210:261-268. doi: 10.1016/j.jss.2016.11.047. Epub 2016 Dec 5.
4
Hyperthermic intraperitoneal chemotherapy (HIPEC) and neoadjuvant chemotherapy as prophylaxis of peritoneal carcinosis from advanced gastric cancer-effects on overall and disease free survival.热灌注腹腔化疗(HIPEC)和新辅助化疗对晚期胃癌腹膜转移癌的预防作用——对总生存期和无病生存期的影响
J Gastrointest Oncol. 2016 Aug;7(4):523-9. doi: 10.21037/jgo.2016.06.05.
5
Impacts of peritoneal cancer index on the survival outcomes of patients with colorectal peritoneal carcinomatosis.腹膜癌指数对结直肠腹膜转移患者生存结局的影响。
Int J Surg. 2016 Aug;32:65-70. doi: 10.1016/j.ijsu.2016.06.033. Epub 2016 Jun 21.
6
Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study.间隔性细胞减灭术及腹腔内热灌注化疗用于晚期卵巢癌一线治疗的可行性研究
Int J Gynecol Cancer. 2016 Jun;26(5):912-7. doi: 10.1097/IGC.0000000000000696.
7
Clinical relevance of high sensitivity C-reactive protein in cardiology.高敏C反应蛋白在心脏病学中的临床相关性。
Medicina (Kaunas). 2016;52(1):1-10. doi: 10.1016/j.medici.2015.12.001. Epub 2016 Jan 15.
8
Postoperative time course and utility of inflammatory markers in patients with ovarian peritoneal carcinomatosis treated with neoadjuvant chemotherapy, cytoreductive surgery, and HIPEC.新辅助化疗、肿瘤细胞减灭术及腹腔热灌注化疗治疗卵巢腹膜癌患者的术后炎症标志物变化过程及应用价值
Ann Surg Oncol. 2015 Apr;22(4):1332-40. doi: 10.1245/s10434-014-4096-5. Epub 2014 Sep 19.
9
Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).通过手术细胞减灭术和腹腔内热灌注化疗(HIPEC)治疗卵巢癌腹膜转移癌。
Minerva Chir. 2014 Feb;69(1):27-35.
10
Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy.识别在接受手术细胞减灭术和腹腔内热化疗后并发症风险最高的患者亚组。
Ann Surg. 2012 Aug;256(2):334-41. doi: 10.1097/SLA.0b013e31825704e3.